TNFRSF17 and plasma cell myeloma: TCE therapies function by binding simultaneously to a target antigen on myeloma cells, such as B-cell maturation antigen (BCMA) or G protein-coupled receptor family C group 5 member D (GPRC5D), and to CD3 receptors on T cells, thereby redirecting T cells to recognize and eliminate malignant plasma cells.